• 1
    CannonG, ed. Food, nutrition and the prevention of cancer: a global perspective. World Cancer Research Fund in association with the American Institute for Cancer Research. Menasha, USA: BANTA Book Group, 1997. 670p.
  • 2
    Sitas F, Madhoo J, Wessie J. Incidence of histologically diagnosed cancer in South Africa, 1993–1995. National Cancer Registry of South Africa, South African Institute for Medical Research, Johannesburg, 1998.
  • 3
    Brown LM, Hoover R, Silverman D, Baris D, Hayes R, Swanson GM, Schoenberg J, Greenberg R, Liff J, Schwartz A, Dosemeci M, Pottern L, et al. Excess incidence of squamous cell esophageal cancer among US African men: role of social class and other risk factors. Am J Epidemiol 2001; 153: 11422.
  • 4
    Pacella-Norman R, Urban MI, Sitas F, Carrara H, Sur R, Hale M, Ruff P, Patel M, Newton R, Bull D, Beral V. Risk factors for oesophageal, lung, oral and laryngeal cancers in Black South Africans. Brit J Cancer 2002; 86: 17516.
  • 5
    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 5770.
  • 6
    Hollstein M, Peri L, Mandard A-M, Welsh JA, Montesano R, Metcalf RA, Bak M, Harris CC. Genetic analysis of human esophageal tumor from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutations. Cancer Res 1991; 51: 41026.
  • 7
    Lu SH, Hsieh LL, Luo FC, Weinstein IB. Amplification of the EGF receptor and c-myc genes in human esophageal cancers. Int J Cancer 1988; 42: 5025.
  • 8
    Jiang W, Zhang YJ, Kahn SM, Hollstein MC, Santella RM, Lu S-H, Harris CC, Montesano R, Weinstein IB. Altered expression of the cyclin D and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci USA 1993; 90: 902630.
  • 9
    Kitagawa Y, Ueda M, Ando N, Shinozawa Y, Shimizu N, Abe O. Significance of int-2/hst-1 coamplification as a prognostic factor in patients with esophageal squamous carcinoma. Cancer Res 1991; 51: 15048.
  • 10
    Xing EP, Nie Y, Wang GY, Yang G-Y, Yang CS. Aberrant methylation of p16INK4a and deletion of p15INK5b are frequent events in human esophageal cancer in Linxian, China. Carcinogenesis 1999; 20: 7784.
  • 11
    Hu N, Roth MJ, Polymeropolous M, Tang Z-Z, Emmert-Buck MR, Wang Q-H, Goldstein AM, Feng S-S, Dawsey SM, Ding T, Zhuang Z-P, Han X-Y, et al. Identification of novel regions of allelic loss from a genomewide scan of esophageal squamous-cell carcinoma in a high-risk Chinese population. Genes Chrom Cancer 2000; 27: 21728.
  • 12
    Yamashita Y, Hirai T, Mukaida H, Kawano K, Toge T, Niimoto M, Hattori T. Detection of androgen receptors in human esophageal cancer. Jpn J Surg 1989; 19: 195202.
  • 13
    Du Plessis L, Dietzsch E, Van Gele M, Van Roy N, Van Helden P, Parker MI, Mugwanya DK, De Groot M, Marx MP, Kotze MJ, Speleman F. Mapping of novel regions of DNA gain and loss by comparative genomic hybridization in esophageal carcinoma in the African and Colored populations of South Africa. Cancer Res 1999; 59: 187783.
  • 14
    Brown CJ, Goss SJ, Lubahn DB, Joseph DR, Wilson EM, French F, Willard HF. Androgen receptor locus on the human X chromosome: regional localization to Xq11–12 and description of a DNA polymorphism. Am J Hum Genet 1989; 44: 2649.
  • 15
    Wilding G. The importance of steroid hormones in prostate cancer. Cancer Surveys 1992; 14: 11330.
  • 16
    Wang C, Uchida T. Androgen receptor mutations in prostate cancer. Nippon Hinyokika Gakkai Zasshi/Jap J Urol 1997; 88: 5506.
  • 17
    Ferro P, Catalano MG, Raineri M, Reato G, dell'Eva R, Risio M, Foa R, Fortunati N, Pfeffer U. Somatic alterations of the androgen receptor CAG repeat in the human colon cancer delineate a novel mutation pathway independent of microsatellite instability. Cancer Genet Cytogenet 2000; 123: 3540.
  • 18
    Hackenberg R, Schulz KD. Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids. J Steroid Biochem Mol Biol 1996; 56: 1137.
  • 19
    Nagasue N, Ito A, Yukaya H, Ogawa Y. Androgen receptors in hepatocellular carcinoma and surrounding parenchyma. Gastroenterology 1985; 89: 6437.
  • 20
    La Spada AR, Wilson E, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991; 352: 779.
  • 21
    Edwards A, Hammond HA, Jin L, Caskey CT, Chakraborty R. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 1992; 12: 24153.
  • 22
    Sleddens HFBM, Oostra BA, Brinkmann AO, Trapman J. Trinucleotide (GGN) repeat polymorphism in the human androgen receptor (AR) gene. Hum Mol Genet 1993; 2: 493.
  • 23
    Hsing AW, Gao Y-T, Wu G, Wang X, Deng J, Chen Y-L, Sesterhenn IA, Mostofi FK, Benichou J, Chang C. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based patient-control study in China. Cancer Res 2000; 60: 51116.
  • 24
    Coetzee GA, Ross RK. Prostate cancer and the androgen receptor. J Natl Cancer Inst 1994; 86: 8723.
  • 25
    Irvine RA, Yu MC, Ross RK, Coetzee, GA. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995; 55: 193740.
  • 26
    Hakimi JM, Schoenberg MP, Rondinelli RH, Piantadosi S, Barrack ER. Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin Cancer Res 1997; 3: 1599608.
  • 27
    Stanford JL, Just JJ, Gibbs M, Wicklund KG, Neal CL, Blumenstein BA, Ostrander EA. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 1997; 57: 11948.
  • 28
    Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Brufsky A, Talcott J, Hennekens CH, Kantoff PW. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997; 94: 33203.
  • 29
    Ingles SA, Ross RK, Yu M, Irvine RA, La Pera G, Haile RW, Coetzee GA. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997; 89: 16670.
  • 30
    Ross RK, Pike MC, Coetzee GA, Reichardt JKV, Yu MC, Feigelson H, Stanczyk FZ, Kolonel LN, Henderson BE. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 1998: 58; 4497504.
  • 31
    Alberts AS. The treatment of squamous cell cancer of the oesophagus—a South African perspective. Understanding Oncology 1991; 2: 1720.
  • 32
    Sambrook J, Fritsch EF, Maniatis T. In: FordC, NolanC, Ferguson, eds. Molecular cloning: a laboratory manual, 2nd ed. pp. 9.149.28. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press, 1989.
  • 33
    Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994; 22: 31816.
  • 34
    Simental J, Madhabananda S, Lane MV, French FS, Wilson EM. Tanscriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 1991; 266: 5108.
  • 35
    Chang B, Zheng SL, Hawkins GA, Isaacs SD, Wiley KE, Turner A, Carpten JD, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB, et al. Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk. Hum Genet 2002; 110: 1229.
  • 36
    Schoenberg MP, Hakimi JM, Wang S, Bova GS, Epstein JI, Fischbeck KH, Isaacs WB, Walsh PC, Barrack ER. Microsatellite mutation (CAG24[RIGHTWARDS ARROW]18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Comm 1994; 198: 7480.
  • 37
    Sasaki M, Dahiya R, Fujimotot S, Ishikawa M, Oshimura M. The expansion of the CAG repeat in exon 1 of the human androgen receptor gene is associated with uterine endometrial carcinoma. Molec Carcinog 2000; 27: 23744.
  • 38
    Yaron M, Levy T, Chetrit A, Levavi H, Sabah G, Schneider D, Halperin R, Ben-Rafael Z, Friedman E. The polymorphic CAG repeat in the androgen receptor gene in Jewish Israeli women with endometrial carcinoma. Cancer 2001; 92: 11904.
  • 39
    Yu M-W, Cheng S-W, Lin M-W, Yang S-Y, Liaw Y-F, Chang H-C, Hsiao T-J, Lin S-M, Lee S-D, Chen P-J, Liu C-J, Chen C-J. Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. J Nat Cancer Inst 2000; 92: 20238.
  • 40
    Rebbeck TR, Kantoff PW, Krithivas K, Neuhausen S, Blackwood MA, Godwin AK, Daly MB, Narod SA, Garber JE, Lynch HT, Weber BL, Brown M. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet 1999; 64: 13717.
  • 41
    Spurdle AB, Dite GS, Chen X, Mayne CJ, Southey MC, Batten LE, Chy H, Trute L, Giles GG, Armes J, Venter DJ, Hopper JL, et al. Androgen receptor exon 1 CAG repeat length and breast cancer in women before age forty. J Natl Cancer Inst 1999; 91: 9616.
  • 42
    Yu H, Bharaj B, Vassilikos EJ, Giai M, Diamandis EP. Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer. Breast Cancer Res Treat 2000; 59: 15361.
  • 43
    Young IE, Kurian KM, MacKenzie MAF, Kunkler IH, Cohen BB, Hooper ML, Wyllie AH, Steel CM. The CAG repeat within the androgen receptor in male breast cancer patients. J Med Genet 2000; 37: 13940.
  • 44
    Kadouri L, Easton DF, Edwards S, Hubert A, Kote-Jarai Z, Glaser B, Durocher F, Abeliovich D, Peretz, Eeles RA. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Br J Cancer 2001; 85: 3640.
  • 45
    Kattar MM, Kupsky WJ, Shimoyama RK, Vo TD, Olson MW, Bargar GR, Sarkar VH. Clonal analysis of gliomas. Hum Pathol 1997; 28: 11179.
  • 46
    Lu KH, Bell DA, Welch WR, Berkowitz R, Mok SC. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumours. Cancer Res 1998; 58: 232830.
  • 47
    Edelson MI, Lau CC, Colitti CV, Welch WR, Bell DA, Berkowitz RS, Mok SC. A one centimorgan deletion unit on chromosome Xq12 is commonly lost in borderline and invasive epithelial tumors. Oncogene 1998; 16: 197202.
  • 48
    Perren A, Roth J, Muletta-Feurer S, Saremaslani P, Speel EJM, Heitz PU, Komminoth P. Clonal analysis of sporadic pancreatic endocrine tumours. J Path 1998; 186: 36371.
  • 49
    D'Adda T, Candidus S, Denk H, Bordi C, Hoefler H. Gastric neuroendocrine neoplasms: tumour clonality and malignancy-associated large X-chromosomal deletions. J Path 1999; 189: 394401.
  • 50
    Indsto JO, Cachia AR, Kefford RF, Mann GJ. X inactivation, DNA deletion and microsatellite instability in common acquired melanocytic nevi. Clin Cancer Res 2001; 7: 40549.
  • 51
    Lee JM, Lee YC, Yang SY, Shi WL, Lee CJ, Luh SP, Chen CJ, Hsieh CY, Wu MT. Genetic polymorphisms of p53 and GSTP1, but not NAT2, are associated with susceptibility to squamous-cell carcinoma of the esophagus. Int J Cancer 2000; 89: 45864.
  • 52
    Shibuta J, Eto T, Kataoka A, Inoue H, Ueo H, Suzuki T, Barnard GF, Mori M. Genetic polymorphism of N-acetyltransferase 2 in patients with esophageal cancer. Am J Gastroenterol 2001; 96: 341924.
    Direct Link:
  • 53
    Lee JM, Lee YC, Yang SY, Yang PW, Luh SP, Lee CJ, Chen CJ, Wu MT. Genetic polymorphisms of XRCC1 and risk of esophageal cancer. Int J Cancer 2001; 95: 2406.
  • 54
    Matsuo K, Hamajima N, Shinoda M, Hatooka S, Inoue M, Takezaki T, Onda H, Tajima K. Possible risk reduction in esophageal cancer associated with MPO-463 A allele. J Epidemiol 2001; 11: 10914.
  • 55
    Kumimoto H, Hamajima N, Nishizawa K, Nishimoto Y, Matsuo K, Harada H, Shimoda M, Hatooka S, Ishizaki K. Different susceptibility of each L-myc genotype to esophageal cancer risk factors. Jpn J Cancer Res 2001; 92: 7359.
  • 56
    Ryan BM, McManus R, Daly JS, Carton E, Keeling PW, Reynolds JV, Kelleher D. A common p73 polymorphism is associated with a reduced incidence of esophageal carcinoma. Br J Cancer 2001; 85: 1499503.
  • 57
    Dragani TA, Canzian F, Pierotti MA. A polygenic model of inherited predisposition to cancer. FASEB J 1996; 10: 86570.
  • 58
    Pharoah PDP, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BAJ. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002; 31: 336.